Vivos Therapeutics (VVOS) Total Liabilities (2019 - 2026)

Vivos Therapeutics (VVOS) has 8 years of Total Liabilities data on file, last reported at $26.3 million in Q1 2026.

• Quarterly Total Liabilities rose 282.69% year-over-year to $26.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.3 million (up 282.69% YoY) and the FY2025 annual result came in at $26.7 million, up 264.28% from the prior year.
• Total Liabilities retreated to $26.3 million in Q1 2026 per VVOS's latest filing, from $26.7 million in the prior quarter.
• Across five years, Total Liabilities topped out at $26.7 million in Q4 2025 and bottomed at $6.9 million in Q1 2025.
• The 5-year median for Total Liabilities is $10.1 million (2023), against an average of $12.8 million.
• The widest annual swing landed in 2025, when Total Liabilities slumped 38.74%; it then jumped 282.69% in 2026.
• Tracing VVOS's Total Liabilities over 5 years: stood at $8.9 million in 2022, then grew by 15.7% to $10.3 million in 2023, then decreased by 28.97% to $7.3 million in 2024, then soared by 264.28% to $26.7 million in 2025, then decreased by 1.47% to $26.3 million in 2026.
• Per Business Quant, the three latest VVOS Total Liabilities figures stand at $26.3 million (Q1 2026), $26.7 million (Q4 2025), and $23.1 million (Q3 2025).

Peer Comparison